SYMBRAVO (Meloxicam; Rizatriptan Benzoate) Patent Expiration, LOE Window & CMS Spending

SYMBRAVO (Meloxicam; Rizatriptan Benzoate) by Axsome Therapeutics: FDA Orange Book core substance LOE 2038-05-18 (last listed 2045-03-10), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,150 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAxsome Therapeutics
FDA Application & PathwayN215431 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-05-18
Last Listed Patent or Exclusivity Date2045-03-10
Orange Book Patents (*PED Extensions)96 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,150 intro WAC)